Disease Burden by Geography
Demand-side intelligence: where the patients actually are.
Country-level disease burden, prevalence trends and unmet-need analysis — for therapy area prioritization, launch sequencing and access strategy.
"Where does the unmet disease burden create real, payable demand?"
Disease burden ≠ pharma opportunity. The right view layers prevalence, diagnosis rates, treatment access and reimbursement to expose where demand is real and payable.
Disease burden is the foundation of every pharma TA strategy — and the most commonly misused dataset. Headline prevalence numbers without diagnosis, access and reimbursement context lead teams into markets that are large on paper and tiny in reality.
Convert burden into payable demand
Prevalence × diagnosed × treated × reimbursed × on-label is the only number that should drive a TA bet. Each multiplier compresses the apparent market — and exposes which geographies are worth prioritizing.
Build a live, country-level view
Decision teams stop using one-time epi reports and instead operate a live demand engine that updates as guidelines, formulary decisions and HTA outcomes change.
What we’re seeing in the data.
Diagnosis gap is the hidden barrier
High prevalence with low diagnosis rates compresses real opportunity by 30–60%.
NCDs dominate growth
Cardio, oncology, diabetes and CKD drive 70%+ of incremental burden through 2035.
Emerging markets shift the geo mix
India, China, Brazil and Indonesia gain share of global burden but cap pricing — model both.
Climate-linked disease shifts patterns
Vector-borne and respiratory disease distributions are moving — durable for 10–20 year forecasts.
How to think about it.
-
01
Start from prevalence data
GBD, WHO and country-specific epi datasets.
-
02
Layer diagnosis rate
Diagnosed prevalence is the real addressable cohort.
-
03
Apply treatment-access filter
Treated rate from claims, registries and HCP audits.
-
04
Score reimbursement reality
Public formulary inclusion, HTA outcomes and out-of-pocket dynamics.
-
05
Express as payable demand
Treated × reimbursed × on-label = the number that drives strategy.
What separates a good answer from a defensible one.
Epi sources disagree — triangulate at least three.
Provincial / state level often matters more than country average.
Aging shifts disease mix toward chronic — model demographic curves.
Cardio-renal-metabolic overlaps inflate single-disease counts.
Where the signal comes from.
Common questions.
How often should this view refresh?
Prevalence yearly; diagnosis and treated rates quarterly with claims; reimbursement live.
How do you handle data conflicts?
Always show ranges across sources with clear assumptions, not single point estimates.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist